BioCryst Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview

BioCryst Pharmaceuticals

23/02/2024 13:54

* BioCryst Pharmaceuticals Inc  BCRX.OQ   BCRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 26 for the period ending December 31 2023
    * The Durham North Carolina-based  company is expected to
report a
13.2% increase in revenue to $90.007 million from $79.55 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data. (Revenue is on total revenue basis)
    * ​LSEG's mean analyst estimate for BioCryst Pharmaceuticals
Inc
is for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.00​, above​ its last closing price
of $5.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.24       -0.23      -0.19     Beat    18.6
 Jun. 30 2023  -0.23       -0.23      -0.24     Missed  -5.1
 Mar. 31 2023  -0.30       -0.30      -0.28     Beat    6.3​
 Dec. 31 2022  -0.13       -0.17      -0.38     Missed  -124.5
 ​​Sep.        -0.29       -0.29      -0.23     Beat    20.9
 30 2022                                                
 Jun. 30 2022  -0.36       -0.34      -0.32     Beat    6.8​
 Mar. 31 2022  -0.35       -0.37      -0.40     Missed  -9.2
 Dec. 31 2021  -0.31       -0.30      -0.10     Beat    67.2
 This summary was machine generated February 23 at 13:54 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)